165 related articles for article (PubMed ID: 22139404)
21. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
[TBL] [Abstract][Full Text] [Related]
22. Turner syndrome adolescents receiving growth hormone are not osteopenic.
Neely EK; Marcus R; Rosenfeld RG; Bachrach LK
J Clin Endocrinol Metab; 1993 Apr; 76(4):861-6. PubMed ID: 8473397
[TBL] [Abstract][Full Text] [Related]
23. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.
Aycan Z; Cetinkaya E; Darendeliler F; Vidinlisan S; Bas F; Bideci A; Demirel F; Darcan S; Buyukgebiz A; Yildiz M; Berberoglu M; Bundak R
Clin Endocrinol (Oxf); 2008 May; 68(5):769-72. PubMed ID: 17980015
[TBL] [Abstract][Full Text] [Related]
24. Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail.
Zhu SY; Deng Y; Wang YF; Xue W; Ma X; Sun A
Gynecol Endocrinol; 2019 Feb; 35(2):165-169. PubMed ID: 30449208
[TBL] [Abstract][Full Text] [Related]
25. Eldecalcitol increases bone mass in patients with Turner syndrome who have insufficient bone mass acquisition after estrogen replacement therapy.
Tsuburai T; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
Endocr J; 2018 Jun; 65(6):629-638. PubMed ID: 29607913
[TBL] [Abstract][Full Text] [Related]
26. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients.
Carrascosa A; Gussinyé M; Terradas P; Yeste D; Audí L; Vicens-Calvet E
J Bone Miner Res; 2000 Oct; 15(10):2005-10. PubMed ID: 11028454
[TBL] [Abstract][Full Text] [Related]
28. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
29. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
[TBL] [Abstract][Full Text] [Related]
30. Volumetric bone mineral density in young women with Turner's syndrome treated with estrogens or estrogens plus growth hormone.
Bertelloni S; Cinquanta L; Baroncelli GI; Simi P; Rossi S; Saggese G
Horm Res; 2000; 53(2):72-6. PubMed ID: 10971092
[TBL] [Abstract][Full Text] [Related]
31. Dosage of estradiol, bone and body composition in Turner syndrome: a 5-year randomized controlled clinical trial.
Cleemann L; Holm K; Kobbernagel H; Kristensen B; Skouby SO; Jensen AK; Gravholt CH
Eur J Endocrinol; 2017 Feb; 176(2):233-242. PubMed ID: 27881458
[TBL] [Abstract][Full Text] [Related]
32. Measurement of bone mineral density (BMD) with quantitative computed tomography (QCT) in postmenopausal osteoporosis: effect of estrogen.
Zgliczyński S; Szulc P; Słowińska-Srzednicka J; Stopińska-Głuszak U; Misiorowski W; Jeske W; Snochowska H; Wagiel K; Walecki J
Endokrynol Pol; 1992; 43(3):350-7. PubMed ID: 1345576
[TBL] [Abstract][Full Text] [Related]
33. Effects of Hormone Replacement Therapy on Bone Mineral Density in Korean Adults With Turner Syndrome.
Kim S; Kim H; Lee I; Choi E; Baek J; Lee J; Kim HR; Yun BH; Choi YS; Seo SK
J Korean Med Sci; 2024 Jan; 39(1):e9. PubMed ID: 38193328
[TBL] [Abstract][Full Text] [Related]
34. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa.
Golden NH; Lanzkowsky L; Schebendach J; Palestro CJ; Jacobson MS; Shenker IR
J Pediatr Adolesc Gynecol; 2002 Jun; 15(3):135-43. PubMed ID: 12106749
[TBL] [Abstract][Full Text] [Related]
35. Final height in estrogen-treated patients with Turner syndrome.
Demetriou E; Emans SJ; Crigler JF
Obstet Gynecol; 1984 Oct; 64(4):459-64. PubMed ID: 6091005
[TBL] [Abstract][Full Text] [Related]
36. Differential time-related effects of conjugated equine estrogen on bone metabolism in oophorectomized women.
Nozaki M; Inoue Y; Hashimoto K; Ogata R; Nakano H
Int J Gynaecol Obstet; 1998 Jan; 60(1):41-6. PubMed ID: 9506413
[TBL] [Abstract][Full Text] [Related]
37. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.
Schneider DL; Barrett-Connor EL; Morton DJ
JAMA; 1997 Feb; 277(7):543-7. PubMed ID: 9032160
[TBL] [Abstract][Full Text] [Related]
38. Decreased bone mass despite long-term estrogen replacement therapy in young women with Turner's syndrome and previously normal bone density.
Lanes R; Gunczler P; Esaa S; Martinis R; Villaroel O; Weisinger JR
Fertil Steril; 1999 Nov; 72(5):896-9. PubMed ID: 10560996
[TBL] [Abstract][Full Text] [Related]
39. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
[TBL] [Abstract][Full Text] [Related]
40. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy.
Rahim A; Holmes SJ; Adams JE; Shalet SM
Clin Endocrinol (Oxf); 1998 Apr; 48(4):463-9. PubMed ID: 9640413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
